Prostate cancer represents growing burden on healthcare systems – direct costs related to its treatment and diagnostics in Slovakia grew by more than 2.5 times from 20 mil EUR in 2014 to 58 mil EUR. Indirect costs related to sick leave and disability doubled during the same period and amounted to 3 mil EUR in 2021.

We presented these facts at our press conference in Bratislava together with Prof. Robert Babela from Slovak Medical University and key expert in urology of the Ministry of Healthcare in Slovakia, Dr. Boris Kollarik. We also presented new diagnostic test developed by Glycanostics – Giasay® Prostate Cancer Test, which is now available to patients in Slovakia in a form of service. We have also presented our plans to obtain CE mark in 2025 and to start full commercial launch in Slovakia, Austria and Germany through laboratory chains.

We strongly believe that these facts will be a great inspiration for the policy makers to develop and implement complex strategies to manage the significantly increasing financial burden caused by prostate cancer in Slovakia.